Pfizer Inc (PFE.N)
LONDON/LOS ANGELES - A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe.
LONDON/LOS ANGELES, March 6 - A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe.
March 3 - Guggenheim Partners has hired Jeff Hoffman and Joseph Kohls as senior managing directors to bolster its healthcare investment banking team, the Wall Street Journal reported.
PARIS, Feb 20 - Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros ($4.8 million) a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake.
NEW YORK, Feb 10 - U.S. stocks rose on Tuesday on hopes that Greek debt negotiations could result in a deal that stabilizes Europe although a drop in oil prices limited the advance.
- Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.
Feb 9 - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.
(The following statement was released by the rating agency) CHICAGO, February 06 (Fitch) Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating action follows Pfizer's announcement that it will acquire Hospira, Inc. (HSP) for roughly $17 billion which includes approximately $1.7 billion in HSP debt. The rating action applies to approximately $38.9 billion of consolidated debt outstanding as of Sept. 28, 2014. The Rating Outloo
NEW YORK, Feb 5 - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.
By Caroline Humer, Ransdell Pierson, Vidya L Nathan and Natalie Grover | Video
|Johnson & Johnson (JNJ.N)||$101.27||-1.25|
|Novartis AG (NOVN.VX)||CHF96.60||+0.30|
|Merck & Co., Inc. (MRK.N)||$57.42||-0.56|
|Roche Holding Ltd. (ROG.VX)||CHF261.30||+5.20|
|Abbott Laboratories (ABT.N)||$46.94||-0.50|
|Bayer AG (BAYGn.DE)||€134.30||+0.95|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€87.89||+0.05|
|AstraZeneca plc (AZN.L)||4,435.00p||-51.50|
|GlaxoSmithKline plc (GSK.L)||1,567.00p||-4.00|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Sadif Analytics Prime
Provider: Thomson Reuters Stock Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.